Table 2 Angiographic and procedural characteristics
No diabetes 2019 (n = 2867) | No diabetes 2020 (n = 2334) | P value | Diabetes 2019 (n = 786) | Diabetes 2020 (n = 622) | P value | |
|---|---|---|---|---|---|---|
Radial Access (%) | 2316 (85) | 1933 (87.3) | 0.019 | 629 (82.9) | 486 (81.4) | 0.84 |
Culpirt vessel Left main—n (%) Left Anterior Descending Artery—n (%) Circumflex—n (%) Right Coronary Artery—n (%) Anterolateral Branch—n (%) SVG—n (%) | 50 (1.8) 1250 (45.9) 386 (14.2) 1021 (37.5) 9 (0.3) 9 (0.3) | 35 (1.6) 993 (45) 347 (15.7) 820 (37) 4 (0.1) 12 (0.5) | 0.54 | 20 (2.6) 340 (44.8) 98 (12.9) 291 (38.3) 2 (0.3) 8 (1.1) | 17 (2.8) 268 (44.9) 91 (15.2) 209 (35) 2 (0.3) 10 (1.7) | 0.64 |
Proximal Lesion location—n (%) | 1343 (49.3) | 1115 (50.4) | 0.48 | 389 (51.3) | 284 (47.6) | 0.43 |
In-stent Thrombosis—n (%) | 97 (3.6) | 93 (4.2) | 0.24 | 53 (7.0) | 35 (5.9) | 0.41 |
Multivesseldisease—n (%) | 1183 (43.4) | 988(44.6) | 0.39 | 411 (54.2) | 358 (60) | 0.032 |
Preprocedural TIMI 0 flow—n (%) | 1674 (61.4) | 1404 (63.4) | 0.15 | 440 (58.0) | 350 (58.6) | 0.81 |
Thrombectomy—n (%) | 526 (19.3) | 390 (17.6) | 0.13 | 126 (16.6) | 99 (16.6) | 0.99 |
Stenting—n (%) | 2509 (92.1) | 2042 (92.2) | 0.84 | 681 (89.7) | 547 (91.6) | 0.23 |
Drug-elutingstent—n (%) | 2480 (91) (91.1) | 2057 (92.9) | 0.015 | 677 (89.2) | 550 (92.1) | 0.068 |
Postprocedural TIMI 3 Flow—n (%) | 2523 (92.6) | 2038 (91.9) | 0.48 | 689 (90.3) | 529 (88.6) | 0.19 |
Gp IIb-IIIa inhibitors/Cangrelor—n (%) | 626 (23.0) | 538 (24.3) | 0.27 | 150 (19.8) | 133 (22.3) | 0.26 |
Bivalirudin—n (%) | 16 (0.6) | 9 (0.4) | 0.37 | 8 (1.1) | 2(0.3) | 0.12 |
Additional PCI During the index procedure—n (%) Staged—n (%) | 389 (14.3) 321 (11.8) | 334 (15.1) 294 (13.3) | 0.16 | 111 (14.6) 94 (12.4) | 108 (18.1) 67 (11.2) | 0.21 |
DAPT therapy—n (%) | 2702 (99.2) | 2194 (99.1) | 0.82 | 751 (98.9) | 583 (97.7) | 0.06 |